AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business UpdateGlobeNewsWire • 05/12/26
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trialsProactive Investors • 04/27/26
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed ResearchGlobeNewsWire • 04/27/26
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderGlobeNewsWire • 04/22/26
AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track OrderBenzinga • 04/20/26
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to SoarThe Motley Fool • 04/20/26
Psychedelics stocks rise after Trump order expands research, access pathwaysProactive Investors • 04/20/26
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.Barrons • 04/20/26
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckleyProactive Investors • 04/14/26
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003Proactive Investors • 04/08/26
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS DrugsGlobeNewsWire • 04/08/26
AtaiBeckley awarded ‘Buy' rating in initial coverage from Deutsche Bank analystsProactive Investors • 03/27/26
AtaiBeckley added to major US indices, increasing reach among passive investorsProactive Investors • 03/24/26
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline CatalystGlobeNewsWire • 03/24/26